JUBLPHARMA

Jubilant Pharmova Share Price

₹1,131.20 +0.7 (0.06%)

21 Nov, 2024 14:25

SIP TrendupStart SIP in JUBLPHARMA

Start SIP

Performance

  • Low
  • ₹1,118
  • High
  • ₹1,157
  • 52 Week Low
  • ₹409
  • 52 Week High
  • ₹1,310
  • Open Price₹1,128
  • Previous Close₹1,131
  • Volume88,875

Investment Returns

  • Over 1 Month -4.11%
  • Over 3 Month + 26.14%
  • Over 6 Month + 57.89%
  • Over 1 Year + 159.84%
SIP Lightning

Smart Investing Starts Here Start SIP with Jubilant Pharmova for Steady Growth!

Invest Now

Jubilant Pharmova Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 30.4
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 18,018
  • P/B Ratio
  • 3.3
  • Average True Range
  • 64.53
  • EPS
  • 18.13
  • Dividend Yield
  • 0.4
  • MACD Signal
  • 18.43
  • RSI
  • 44.08
  • MFI
  • 49.13

Jubilant Pharmova Financials

Jubilant Pharmova Technicals

EMA & SMA

Current Price
₹1,131.20
+ 0.7 (0.06%)
pointer
  • stock-down_img
  • Bullish Moving Average 6
  • stock-up_img
  • Bearish Moving Average 10
  • 20 Day
  • ₹1,177.19
  • 50 Day
  • ₹1,127.24
  • 100 Day
  • ₹1,021.54
  • 200 Day
  • ₹869.81

Resistance and Support

1137.82 Pivot Speed
  • R3 1,213.58
  • R2 1,190.77
  • R1 1,160.63
  • S1 1,107.68
  • S2 1,084.87
  • S3 1,054.73

What's your outlook on Jubilant Pharmova?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Jubilant Pharmova Ltd. is a global pharmaceutical company engaged in radiopharma, allergy immunotherapy, CDMO sterile injectables, CRDMO, and generics. It operates manufacturing facilities across regulated markets, offering innovative solutions in oncology, autoimmune disorders, and various therapeutic areas.

Jubilant Pharmova has an operating revenue of Rs. 6,919.70 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 2% needs improvement, ROE of 1% is fair but needs improvement. The company has a debt to equity of 58%, which is bit higher. The stock from a technical standpoint is trading below to its 50DMA and around 38% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 90 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Jubilant Pharmova Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-07-19 Quarterly Results
2024-05-29 Audited Results & Final Dividend
2024-02-02 Quarterly Results
2023-10-27 Quarterly Results
Date Purpose Remarks
2024-08-02 FINAL Rs.5.00 per share(500%)Final Dividend
2023-08-10 FINAL Rs.5.00 per share(500%)Final Dividend
2022-08-12 FINAL Rs.5.00 per share(500%)Final Dividend
2021-08-06 FINAL Rs.5.00 per share(500%)Final Dividend

Jubilant Pharmova F&O

Jubilant Pharmova Shareholding Pattern

50.68%
3.06%
0.64%
17.94%
0%
18.09%
9.59%

About Jubilant Pharmova

  • NSE Symbol
  • JUBLPHARMA
  • BSE Symbol
  • 530019
  • Managing Director
  • Mr. Priyavrat Bhartia
  • ISIN
  • INE700A01033

Similar Stocks to Jubilant Pharmova

Jubilant Pharmova FAQs

Jubilant Pharmova share price is ₹1,131 As on 21 November, 2024 | 14:11

The Market Cap of Jubilant Pharmova is ₹18017.9 Cr As on 21 November, 2024 | 14:11

The P/E ratio of Jubilant Pharmova is 30.4 As on 21 November, 2024 | 14:11

The PB ratio of Jubilant Pharmova is 3.3 As on 21 November, 2024 | 14:11

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23